| 52nd week of 2012 patent applcation highlights part 40 |
| Patent application number | Title | Published |
|---|
| 20120328512 | Fibrin-Binding Peptides and Conjugates Thereof - Fibrin-binding peptides having high binding affinity and excellent physical characteristics compared to previously known fibrin-binding peptides are provided. These fibrin-binding peptides may be conjugated to a detectable label or a therapeutic agent and used to detect and facilitate treatment of pathological conditions associated with the presence of fibrin such as thrombic, angiogenic and neoplastic conditions. These peptides may be used in imaging processes such as MRI, ultrasound and nuclear medicine imaging (e.g. PET, scintigraphic imaging, etc.). The peptides may also be used therapeutically. The present invention also provides processes and methods for making and using such peptides and conjugates thereof. | 2012-12-27 |
| 20120328513 | COMPOSITIONS AGAINST CANCER ANTIGEN LIV-1 AND USES THEREOF - Described herein are methods and compositions that can be used for diagnosis and treatment of cancer. | 2012-12-27 |
| 20120328514 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS - The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter. | 2012-12-27 |
| 20120328515 | IN VIVO DETECTION OF APOPTOSIS - The invention provides methods and products, such as kits, useful for determining the apoptotic state of cells in an organism. | 2012-12-27 |
| 20120328516 | METHOD OF RADIOTHERAPY USING A RADIOLABELLED RGD PEPTIDE - The present invention relates to a method of radiotherapy, in particular image-guided radiotherapy (IGRT), where radiolabelled RGD peptides are used to provide a tumour angiogenesis volume. Also provided are methods of determination of the gross tumour volume as well as methods of radiotherapy monitoring using such peptides. | 2012-12-27 |
| 20120328517 | KALLIKREIN-BINDING "KUNITZ DOMAIN" PROTEINS AND ANALOGUES THEREOF - This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides. | 2012-12-27 |
| 20120328518 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS - This invention relates to novel compounds suitable for labelling by | 2012-12-27 |
| 20120328519 | DENTRIC POLYGLYCEROL SULFATES AND SULFONATES AND THEIR USE FOR INFLAMMATORY DISEASES - The present invention relates to the novel compound classes of dendritic polyglycerol sulfates and sultanates as well as to their production and use for the treatment of diseases, particularly inflammatory diseases, and to their use as selectin inhibitors and selectin indicators. The dendritic polyglycerol sulfates and sulfonates are also suitable for imaging diagnostics, particularly with respect to inflammatory diseases. | 2012-12-27 |
| 20120328520 | CONJUGATE WITH TARGET-FINDING LIGAND AND USE THEREOF - Described is a conjugate of agent complex and at least one target-finding ligand, where the agent complex comprises an agent encapsulated by an encapsulation material and where the target-finding ligand is a prostacyclin analog, and the use of the conjugate. | 2012-12-27 |
| 20120328521 | FORMULATIONS SUITABLE FOR PET IMAGING WITH HYDROPHOBIC PET AGENTS - The invention is directed to formulations of lipophilic Amyloid βeta ligand stilbene based derivatives and more particularly to formulations which are administrable parentally e.g. intravenously wherein the lipophilic Amyloid βeta ligand stilbene based derivative is a | 2012-12-27 |
| 20120328522 | DIAGNOSTIC COMPOSITION COMPRISING PLASMA CATIONS HAVING SUPERIOR SAFETY PROFILE - The present invention relates to a new diagnostic X-ray composition which exhibits a superior cardiac safety profile. The composition comprises a non-ionic iodinated dimer in a pharmaceutically acceptable carrier. More particularly, the invention provides a diagnostic composition comprising a Compound I, a pharmaceutically acceptable carrier, and dissolved therein a sodium compound and a calcium compound providing a sodium ion concentration of 40-50 mM and a calcium ion concentration of 0.1-0.7 mM. The invention also relates to methods of imaging using such diagnostic compositions. | 2012-12-27 |
| 20120328523 | POLYHYDROXYALKANOATES FOR IN VIVO APPLICATIONS - Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial system (RES), are described. Methods for depyrogenating PHA polymers prepared by bacterial fermentation processes are also provided, wherein pyrogens are removed from the polymers without adversely impacting the polymers' inherent chemical structures and physical properties. PHAs with advantageous processing characteristics, including low melting points and/or solubility in non-toxic solvents, are also described. The PHAs are suitable for use in in vivo applications such as in tissue coatings, stents, sutures, tubing, bone, other prostheses, bone or tissue cements, tissue regeneration devices, wound dressings, drug delivery, and for diagnostic and prophylactic uses. | 2012-12-27 |
| 20120328524 | ANTI-GD2 ANTIBODIES AND METHODS AND USES RELATED THERETO - Described herein are antibodies that specifically bind ganglioside GD2. Also described are nucleotides encoding such antibodies, cells expressing such antibodies, methods of use for such antibodies, and methods for using the antibodies to treat diseases associated with ganglioside GD2. In addition, tissue culture media supplements are described as are methods of use for the supplements. Described herein are albumin-ganglioside conjugates and corresponding methods for producing such conjugates. Methods of purifying or isolating antibodies are also described. | 2012-12-27 |
| 20120328525 | NANOPARTICLE COMPOSITIONS AND COMPONENTS THEREOF - The present invention describes systems and methods for treating disorders and/or conditions associated with the dermal level of the skin. Such disorders include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal infection, and/or actinic keratosis, among others. Methods generally involve administering provided compositions to the skin. | 2012-12-27 |
| 20120328526 | Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof - The present invention provides a method of treating a mammal having a neuropathophysiological condition, comprising the step of administering to the mammal in need of such treatment a compound selected from nicotinamide or salts or prodrugs thereof, nicotinamide mononucleotide or salts or prodrugs thereof, nicotinamide adenine dinucleotide or salts or prodrugs thereof, nicotinamide riboside nicotinamide or salts or prodrugs thereof, phosphoribosyltransferase, or combinations thereof. Further provided is a method for treating a mammal having a neuropathophysiological condition or suspected to develop said neuropathophysiological condition, comprising the step of administering to said mammal an inhibitor of CD38 NAD | 2012-12-27 |
| 20120328527 | METHODS OF ENHANCING FUNCTIONING OF THE LARGE INTESTINE - The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases. | 2012-12-27 |
| 20120328528 | MONOCLONAL ANTIBODY AGAINST NECROSIS MARKER PRDX4 AND USE THEREOF - [PROBLEM] To provide a monoclonal antibody against a biomarker which shows high specificity and can be effectively used in detection and diagnosis of various lesions relevant to various kinds of carcinomas and foci of necrosis, and so forth. | 2012-12-27 |
| 20120328529 | MICROFLUIDIC-BASED GENERATION OF FUNCTIONALIZED MICROBUBBLES FOR ULTRASOUND IMAGING AND THERAPY - A method for generating stable encapsulated bubbles and dried encapsulated bubbles comprises introducing an inner stream of a gas into a liquid-filled chamber from an exit orifice of a capillary tube; introducing a middle stream of a water immiscible liquid into the exit orifice; and introducing an outer stream of an aqueous liquid to the exit orifice, to form compound bubbles. The encapsulated bubbles are formed after converting the middle phase of compound bubbles into a shell. The stable encapsulated bubbles or the stable dried encapsulated bubbles can be used in drug delivery and for enhancing ultrasound imaging. | 2012-12-27 |
| 20120328530 | TOLUIDINE BLUE DERIVATIVES AS PHOTOSENSITISING COMPOUNDS - A compound of formula (III), or a pharmaceutically acceptable derivative thereof for use in a method of combating and/or detecting a pathogen and/or tumour cells; wherein X is selected from O, S and Se; each of R | 2012-12-27 |
| 20120328531 | STABLE LIQUID DESOXIMETHASONE COMPOSITIONS WITH REDUCED OXIDIZED IMPURITY - The present invention relates to a stable liquid formulation comprising desoximetasone, isopropyl myristate, a C | 2012-12-27 |
| 20120328532 | COMPOSITION FOR SHAPING KERATIN FIBERS CONTAINING STARCHES MODIFIED WITH PROPYLENE OXIDE - Cosmetic agents for temporarily reshaping keratin fibers, particularly human hair, containing in a cosmetic carrier at least one starch modified with propylene oxide, the starch having an average molecular weight (weight-average) of 50 to 2,500 kDa and a propylene oxide content of 4 to 6 wt. % (based on weight of the starch modified with propylene oxide), wherein the agents achieve styling with a good degree of hold and elevated flexibility. The propylene oxide-modified starches are based on renewable raw materials. Here, effective styling agents for hair can be provided without having to rely on setting polymers obtained from fossil fuels. | 2012-12-27 |
| 20120328533 | HYPNOTIC COMPOSITIONS AND METHODS OF USE THEREOF - The present invention provides a chewing gum for treatment of sleep apnea. The chewing gum includes indiplon or a pharmaceutically acceptable salt thereof, a gum base, a protecting agent, a carbonate salt, a citrate salt, and a borate salt. The present invention also includes methods of treating narcolepsy, which include the step of administering a dosage form to a patient suffering from narcolepsy. The dosage form includes zopeclon or a pharmaceutically acceptable salt thereof, a bicarbonate salt, a metal oxide, and a phosphate salt. The dosage form could be a lyophilized powder or a chewing gum. | 2012-12-27 |
| 20120328534 | ENZYMATIC PERACID GENERATION FOR USE IN ORAL CARE PRODUCTS - Disclosed herein are compositions and methods to treat an oral cavity surface with a peracid-based benefit agent. The peracid benefit agent can be use for oral surface bleaching, whitening, disinfecting, destaining, deodorizing, decreasing or removing biofilm, and combinations thereof. The peracid is enzymatically generated from a carboxylic acid ester substrate using a CE-7 carbohydrate esterase having perhydrolytic activity (perhydrolase) in the presence of a source of peroxygen. A fusion protein comprising the perhydrolase coupled to a peptidic component having affinity for an oral cavity surface, either directly or through an optional linker, may be used to target the perhydrolytic activity to the oral cavity surface. | 2012-12-27 |
| 20120328535 | TOOTH WHITENING COMPOSITION - A tooth whitening composition for whitening a surface of a tooth, the composition comprising a mixture of a whitening agent comprising an aqueous peroxide, a hydrophobic polymer carrier for adhering the tooth whitening composition to a tooth surface and at least one adhesion enhancing agent. | 2012-12-27 |
| 20120328536 | Taste Improving Substances - The present invention relates to taste improvement of foodstuffs, beverages, tobacco products and oral care products, using a substance according to formula (I), edible salts or edible esters thereof: | 2012-12-27 |
| 20120328537 | Topical wound management formulation - A topical wound therapeutic treatment provides a gel preparation of very low toxicity and good antimicrobial properties. The gel can be formulated for both intra-oral and extra-oral use. The preparation uses high concentration Xylitol in combination with other agents including a non-Xylitol, sugarless, antimicrobial sweetener, such as DL-Menthol, oil of Peppermint, Sorbitol and Glycerin to achieve rapid wound healing with comfort. The dried gel forms a water soluble occlusive dressing to promote healing. | 2012-12-27 |
| 20120328538 | Glycerine Based Jelly Compositions - The present disclosure describes a replacement for petroleum jelly as a base for products which is suitable for most any application for which petroleum jelly can be used. The jelly is a glycerine based jelly composition comprising; vegetable derived glycerine and an emulsifier, wherein the emulsifier can be any known and/or commercially available glucoside containing emulsifier. Other suitable emulsifiers together with glycerine and essential or vegetable based oils with or without inorganic fillers may also be added to the jelly to impart fragrance, color, UVA and UVB sun protection factor(s), immuno-enhancing aromatherapeutics, as well as free radical scavenging constituents. In addition, temperature stabilizers and stiffening agents such as waxes and other inorganic fillers including silica and clays may also be added during manufacture as required. The glycerine is preferably present in the range of 50-95%. Other ingredients which may be added include vitamins and provitamins, carotenoids, as well as aloe vera gel or juice. | 2012-12-27 |
| 20120328539 | Thickener Or Gellant For Oil Materials, Gel Composition Comprising Same, And Method Of Producing Cosmetic Material Or Topical Agent - This inventive thickener or gellant for oil materials is characterized by comprising (A) an high molecular weight organopolysiloxane that has a polyglycerol structure-containing hydrophilic group Q and that is represented by the following structural formula (1): R | 2012-12-27 |
| 20120328540 | Cysteinyl compounds, compositions and methods of use - Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, the compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing the same compounds and the use thereof for the treatment of diseases that may benefit from edema, erythema and MPO inhibition, such as inflammation (acute or chronic), asthma, autoimmune diseases, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis and small airways disease, etc.), inflammatory responses of the immune system, skin diseases (e.g., reducing acute skin irritation for patients suffering from rosacea, atopic dermatitis, seborrheic dermatitis, psoriasis), irritable bowel syndrome (e.g., Chron's disease and ulcerative colitis, etc.), and central nervous system disorders (e.g., Parkinson's disease). | 2012-12-27 |
| 20120328541 | Anti-radical agents - Compounds of the formulae | 2012-12-27 |
| 20120328542 | COSMETIC TREATMENT METHOD USING A COMPOUND THAT CAN BE CONDENSED IN SITU AND A UV-RADIATION-FILTERING AGENT - The present invention relates to a method for the cosmetic treatment of the skin, comprising the application, to the skin:
| 2012-12-27 |
| 20120328543 | USE OF A CATIONIC, ADVANTAGEOUSLY AMPHOTERIC, SURFACTANT FOR THE PREPARATION OF AN ANTIFUNGAL SOLUTION THAT CAN BE APPLIED TO THE NAIL - The use of a cationic surfactant, or an amphoteric surfactant, for the preparation of a composition comprising an antifungal agent in the form of an acid salt, intended to be applied to the nail is described. | 2012-12-27 |
| 20120328544 | Dermatological Treatment Methods And Formulations - A dermatological composition for application to the skin or nails comprises a salt of a cation and an anion. The cation is derived from a monomeric or polymeric molecule that will generate an amidine moiety, a guanidine moiety or a biguanide moiety. The anion is derived from a monomeric or polymeric molecule that will generate a carboxylic acid moiety. The composition may be prepared by a metathesis or acid-base reaction. | 2012-12-27 |
| 20120328545 | METHOD FOR TREATING VASCULAR INFLAMMATION, IMPROVING SKIN BEAUTY AND IMPROVING MALE SEXUAL FUNCTION USING GINSENG BERRY - The present disclosure discloses a method for treating vascular inflammation, improving skin beauty and improving male sexual function of a subject by administering a ginseng berry extract to the subject. | 2012-12-27 |
| 20120328546 | Paxillin Stimulating Compositions and Cosmetic Uses Thereof - Cosmetic compositions comprising one or more paxillin stimulators and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. The paxillin stimulators and combinations thereof are believed to have modulatory activity against at least one biochemical pathway implicated in skin aging. | 2012-12-27 |
| 20120328547 | Cosmetic Composition Comprising Siliconed Sapucainha Ester and a Cosmetic Product Comprising Said Composition - The present invention relates to a cosmetic composition comprising siliconed sapucainha ester, compound which can be used as a cosmetic excipient replacing silicones for several applications. | 2012-12-27 |
| 20120328548 | SANITIZING COMPOSITIONS - Provided are novel compositions exhibiting highly effective antiviral, antimicrobial and/or antifungal activity. The compositions of the invention can be used for sanitizing and/or disinfecting surfaces, e.g., inanimate and/or animate surfaces. Preferred compositions include a synergistic combination of an alcohol, docusate, geraniol and, optionally, menthol. The invention provides compositions that have high antimicrobial activity, yet are mild, non-irritating, quick drying, non-sticky and not drying to the skin. Processes for manufacturing and using the compositions and products containing such compositions are also disclosed. | 2012-12-27 |
| 20120328549 | OIL COMPOSITIONS - The present invention provides oil compositions and associated methods and reagents, particularly useful for the treatment of dermatologic conditions. In some embodiments, provided compositions are formulated for and achieve transdermal delivery, for example by topical administration. | 2012-12-27 |
| 20120328550 | LEAVE-IN HAIR DYEING PROCESS USING A COMPOSITION COMPRISING A COLOURED POLYMER AND AN ACTIVE COSMETIC AGENT - The invention relates to a leave-in hair dyeing process using a composition comprising a coloured polymer and an oil. Such a process makes it possible to obtain a coloration which is easy to carry out and which preserves the cosmetic appearance of the keratin fibres. | 2012-12-27 |
| 20120328551 | HAIR COSMETIC - The present invention provides a hair cosmetic comprising the following ingredients (a) through (c):
| 2012-12-27 |
| 20120328552 | MULTI-PHASE PERSONAL CARE COMPOSITION - A multi-phase personal care composition comprising at least two visually distinct phases in physical contact with one another characterised in that at least one phase comprises polyacrylate-1 crosspolymer. | 2012-12-27 |
| 20120328553 | METHOD AND ANTIBACTERIAL/ANTIMICROBIAL COMPOSITIONS IN DENTAL COMPOSITIONS - Disclosed herein is a composition and method of making a polymerizable antibacterial/antimicrobial resin and using such a bioactive resin in formulated dental compositions. | 2012-12-27 |
| 20120328554 | Composition for the Preparation of an Anti-Biofouling Coating - The present invention is related to a composition for the preparation of an anti-biofouling coating comprising: -a polymer fraction essentially consisting of polysiloxane; -a curing agent; -carbon nanotubes; -a metal-free catalyst consisting of an organic acid. | 2012-12-27 |
| 20120328555 | DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER - The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. | 2012-12-27 |
| 20120328556 | Peptide Based Antimicrobial Coating - A comb-like surfactant polymer for changing the surface properties of biomaterials is described. The surfactant polymer comprises a polymeric backbone of repeating monomeric units having functional groups for chemically attaching to side chains, a plurality of hydrophobic side chains attached to the backbone via the functional groups and a plurality of hydrophilic side chains chemically attached via functional groups to the polymeric backbone. The hydrophilic side chains providing anti-thrombogenic properties to the surfactant. An antimicrobial agent selectively attached to some hydrophilic side chains thereby providing additional antimicrobial properties to the surfactant. The surfactant polymer may be applied to the surface of medical devices to reduce the surfaces thrombogenicity and decrease the number of microorganisms on the surface. | 2012-12-27 |
| 20120328557 | ADHESIVE CELL TISSUE GELS - Described herein is a cell tissue gel cross-linked with a cross-linking agent, and a quenching agent bound to a reactive group of the cross-linking agent. | 2012-12-27 |
| 20120328558 | ANTIBODY-LIGHT FUSION PRODUCTS FOR CANCER THERAPEUTICS - Antibody-LIGHT fusion products or conjugates stimulate immunity against tumors and eradicate metastases. Tumor-specific antibodies coupled with LIGHT effectively target metastatic tumors and reduces cancer metastases. | 2012-12-27 |
| 20120328559 | Compositions and Methods for Treating Inflammatory Lung Disease - The invention provides a method of modulating a T cell immune response by modulating DR3 function in the T cell, wherein the T cell response causes a symptom of inflammatory lung disease. The invention also provides a method of treating a reactive airway disease in an animal subject by administering to the subject an agent which modulates at least one functional activity of CD30. The invention additionally provides a method for treating an inflammatory lung disease by administering an agent that decreases the activity of DR3 or CD30, whereby IL-13 expression is decreased. | 2012-12-27 |
| 20120328560 | METHOD FOR OBTAINING BIOLOGICALLY ACTIVE RECOMBINANT HUMAN G-CSF - Provided is a method of obtaining biologically active recombinant human G-CSF from inclusion bodies, wherein the solubilization and refolding process can be performed at ambient temperature and the purification step comprises reversed phase chromatography (RP), in particular RP-HPLC. The G-CSF preparation so obtained is characterized by high purity and homogeneity. | 2012-12-27 |
| 20120328561 | METHOD FOR TREATMENT OF INFLAMMATORY GASTROINTESTINAL DISORDERS - Providing a new method of treating inflammatory gastrointestinal disorders and a food product for the prevention or improvement of inflammatory gastrointestinal disorders. Prevention or treatment of inflammatory gastrointestinal disorders is possible by oral administration of recombinant IL-10 expressed in rice plant seeds. | 2012-12-27 |
| 20120328562 | METHOD AND SYSTEM TO REMOVE SOLUBLE TNFR1, TNFR2 AND IL2 IN PATIENTS - A method, and system, to induce remission in diseases characterized by excess production of sTNR and interleukin 2 has been developed. In the most preferred embodiment, the system consists of antibodies to sTNFR1, sTNFR2 and sIL2R immobilized in a column containing a material such as SEPHAROSE™. The patient is connected to a pheresis machine which separates the blood into the plasma and red cells, and the plasma is circulated through the column until the desired reduction in levels of sTNFR1, sTNFR2, and IL2 is achieved, preferably to less than normal levels. In the preferred method, patients are treated three times a week for four weeks. This process can be repeated after a period of time. Clinical studies showed reduction in tumor burden in patients having failed conventional chemotherapy and radiation treatments. | 2012-12-27 |
| 20120328563 | CD4+CD25+ REGULATORY T CELLS FROM HUMAN BLOOD - The present invention provides suppressive and/or regulative human CD4 | 2012-12-27 |
| 20120328564 | Camptothecin-Binding Moiety Conjugates - The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates. | 2012-12-27 |
| 20120328565 | ANTIVIRAL COMPOUNDS - The present invention discloses compounds of Formula I | 2012-12-27 |
| 20120328566 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES - The present invention relates to treatment of neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease, using an estrogen receptor beta (ERβ) ligand in combination with a standard, anti-inflammatory agent. | 2012-12-27 |
| 20120328567 | BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNB AND USES THEREOF - Methods, assays and kits for the identification, assessment and/or treatment of a subject having multiple sclerosis (MS) (e.g., a patient with relapsing-remitting multiple sclerosis (RRMS)) are disclosed. | 2012-12-27 |
| 20120328568 | COMPOSITIONS AND USES OF LECTINS - The disclosure relates to uses of a purified or isolated lectin to kill bacteria, viruses, and other pathogens. In certain embodiments, the disclosure relates to method of treating or preventing an infection comprising administering a purified or isolated galectin to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, or diagnosed with a pathogenic infection. | 2012-12-27 |
| 20120328569 | INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE - Disclosed are compounds of formula (I) that are used as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. | 2012-12-27 |
| 20120328570 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2012-12-27 |
| 20120328571 | Method for Using a Bacillus Subtilis Strain for Prophylaxis and Treatment of Gastro-Intestinal Conditions - The present invention relates to a method for enhancing the health of a human comprising administering to the human an effective amount of a composition comprising | 2012-12-27 |
| 20120328572 | BACILLUS BACTERIA FOR USE IN TREATING AND PREVENTING INFECTION IN AQUATIC ANIMALS - Disclosed herein are microbiocidal compositions that include spore-forming strains of | 2012-12-27 |
| 20120328573 | Composition for Maintaining Healthy Kidney Function - The present invention provides a composition comprising prebiotic and probiotic components and is used to reduce elevated levels of nitrogenous waste products and to promote a healthy bowel microenvironment. | 2012-12-27 |
| 20120328574 | P38 INHIBITORS - The invention relates to novel p38 MAPK inhibitor which involves | 2012-12-27 |
| 20120328575 | Modified Oncolytic Viruses - The present invention provides an isolated selected Picornavirus capable of lytically infecting or inducing apoptosis in a cell substantially in the absence of intercellular adhesion molecule-1 (ICAM-1), and methods for treating subjects. | 2012-12-27 |
| 20120328576 | DEFINED DOSE THERAPEUTIC PHAGE - The invention provides therapeutic, defined-dose anti-bacterial phage preparations, methods to make such preparations, methods to treat bacterial infections using such preparations and methods to diagnose bacterial infections using such preparations. | 2012-12-27 |
| 20120328577 | INHIBITION OF BIOFILMS IN PLANTS WITH IMIDAZOLE DERIVATIVES - Disclosure is provided for methods of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, including applying thereto a treatment effective amount of an active compound as described herein, or an agriculturally acceptable salt thereof. Methods of enhancing a microbicide (e.g., including a copper, antibiotic, bacteriophage, etc.) and/or plant defense activator are also provided, including applying an active compound as described herein. Compositions comprising an active compound as described herein in an agriculturally acceptable carrier are also provided, and in some embodiments the compositions further include a microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or plant defense activator. | 2012-12-27 |
| 20120328578 | PRIMED STEM CELLS AND USES THEREOF TO TREAT INFLAMMATORY CONDITIONS IN JOINTS - Disclosed are methods of treating inflammation within a synovial joint, comprising administering to the joint a composition comprising primed stem or progenitor cells in an amount effective to enhance recovery, and a pharmaceutically acceptable carrier. | 2012-12-27 |
| 20120328579 | HUMAN TROPHOBLAST STEM CELLS AND USE THEREOF - Existence of human trophoblast stem (hTS) cells has been suspected but unproved. The isolation of hTS cells is reported in the early stage of chorionic villi by expressions of FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. These facts suggest that differentiation of the hTS cells play an important role in implantation and placentation. hTS cells could be apply to human cell differentiation and for gene and cell-based therapies. | 2012-12-27 |
| 20120328580 | COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION - This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation. | 2012-12-27 |
| 20120328581 | TISSUE REPAIR - According to the invention there is provided a cosmetic method for the augmentation of subcutaneous or dermal tissue in a subject, which method comprises the steps of: | 2012-12-27 |
| 20120328582 | Primate Embryonic Stem Cells - A purified preparation of primate embryonic stem cells is disclosed. This preparation is characterized by the following cell surface markers: SSEA-1 (−); SSEA-4 (+); TRA-1-60 (+); TRA-1-81 (+); and alkaline phosphatase (+). In a particularly advantageous embodiment, the cells of the preparation are human embryonic stem cells, have normal karyotypes, and continue to proliferate in an undifferentiated state after continuous culture for eleven months. The embryonic stem cell lines also retain the ability, throughout the culture, to form trophoblast and to differentiate into all tissues derived from all three embryonic germ layers (endoderm, mesoderm and ectoderm). A method for isolating a primate embryonic stem cell line is also disclosed. | 2012-12-27 |
| 20120328583 | TREATMENT OF PAIN USING PLACENTAL STEM CELLS - Provided herein are methods of treatment of an individual having pain, e.g., neuropathic pain, comprising administering to the individual a therapeutically effective amount of tissue culture plastic adherent placental stem cells (PDAC™). | 2012-12-27 |
| 20120328584 | Biological Pacemaker - Disclosed are methods and systems for modulating electrical behavior of cardiac cells. Preferred methods include administering a polynucleotide or cell-based composition that can modulate cardiac contraction to desired levels, i.e., the administered composition functions as a biological pacemaker. | 2012-12-27 |
| 20120328585 | Nutritional Composition Having Prebiotic - The present invention is directed to a novel method for increasing the production of acetate, decreasing the production of butyrate, increasing the population and species of beneficial bacteria and slowing the rate of fermentation of prebiotics within the gut of a formula-fed infant. The method comprises administration of a therapeutically effective amount of PDX to the infant. | 2012-12-27 |
| 20120328586 | METHODS AND MEANS FOR PROTECTING THE SKIN AGAINST PATHOGENIC MICROORGANISMS - Described are microorganisms which are, in a first aspect, able to stimulate the growth of microorganisms of the resident skin microbial flora and which do not stimulate the growth of microorganisms of the transient pathogenic micro flora. In a second aspect microorganisms are described which are able to inhibit the growth of microorganisms of the transient pathogenic skin micro flora and which do not inhibit the growth of microorganisms of the resident skin micro flora. Also described are compositions comprising such microorganisms as well as the use of such microorganisms in cosmetic, prophylactic or therapeutic applications. | 2012-12-27 |
| 20120328587 | Method for Activating Natural Killer Cells by Tumor Cell Preparation In Vitro - The present invention provides a method for activating a Natural Killer (NK) cell by contacting the NK cell in vitro with an activating tumour cell preparation (ATCP). The invention also provides an activated NK cell produced by such a method and its use in the treatment of cancer. | 2012-12-27 |
| 20120328588 | COMPOUND PREPARATION AND ITS USES FOR PREVENTION AND TREATMENT OF HEARING IMPAIRMENT - A compound preparation contains alpha-lipoic acid and nimodipine at a ratio from 5:1 to 40:1. The above-mentioned compound preparation can be used for the prevention and treatment of noise-induced hearing impairment. This compound preparation not only increases the efficacy but decreases the dosage of nimodipine, reduces the side effects and improves the patient compliance. | 2012-12-27 |
| 20120328589 | GLUCOCEREBROSIDASE MULTIMERS AND USES THEREOF - Multimeric protein structures comprising at least two glucocerebrosidase molecules being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and uses thereof in the treatment of Gaucher disease. The multimeric protein structures are characterized by longer-lasting activity as compared to native glucocerebrosidase both in serum and in lysosomes. | 2012-12-27 |
| 20120328590 | ANTI-CANCER THERAPEUTIC STRATEGY TO OVERCOME CANCER RESISTANCE AND TO ENABLE TAILORING TREATMENT TO PATIENTS - A gene construct comprising a programmed-cell-death executioner gene having a nuclear localization signal, a deleted signal peptide, an inhibitor-resistant binding site, a promoter, and an activator. A method of making a gene construct, by modifying a programmed-cell-death executioner gene by adding a nuclear localization signal, deleting a signal peptide, mutating a binding site for an inhibitor to make it inhibitor-resistant, adding a promoter for exclusive expression in selected cells, and adding an activator. A method of eliminating undesired cells from a patient. A method of treating cancer. An array comprising at least two gene constructs wherein all of the gene constructs differ with respect to the programmed-cell-death executioner gene and the nuclear localization signal. A method of personalizing anti-cancer treatment. A method of increasing DNase 1 resistance to actin binding. A method of increasing catalytic activity of DNase 1 binding. | 2012-12-27 |
| 20120328591 | METHODS FOR IMPROVING ORAL DELIVERY - The invention provides a method of improving the oral delivery of a therapeutic agent, comprising the step of linking the therapeutic agent to a carrier protein comprising angiogenin, fusion proteins or conjugates comprising angiogenin and a therapeutic agent and their use in medicine. | 2012-12-27 |
| 20120328592 | STABILIZED ALPHA-GALACTOSIDASE AND USES THEREOF - Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment. | 2012-12-27 |
| 20120328593 | Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites - The teachings provided herein generally relate to site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites. More particularly, the systems taught here include a phenolic compound bound to a reactive oxygen species, wherein the phenolic compound and the reactive oxygen species react at a target area in the presence of an oxidoreductase enzyme. | 2012-12-27 |
| 20120328594 | PROTEIN AND LIPID BIOMARKERS PROVIDING CONSISTENT IMPROVEMENT TO THE PREDICTION OF TYPE 2 DIABETES - The invention relates to biomarkers associated with Diabetes, including protein and lipid metabolite biomarkers, methods of using the biomarkers to determine the risk that an individual will develop Diabetes, and methods of screening a population to identify persons at risk for developing Diabetes and other pre-diabetic conditions. | 2012-12-27 |
| 20120328595 | VARIANT ACTIVIN RECEPTOR POLYPEPTIDES AND USES THEREOF - The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided. | 2012-12-27 |
| 20120328596 | USE OF PLATELET ACTIVATING FACTOR ACETYLHYDROLASE AS A BIOMARKER FOR ANAPHYLAXIS - The invention provides a use of platelet activating factor acetylhydrolase (PAF-AH) activity as a biomarker for severe or fatal anaphylaxis in a subject. The level of PAF-AH activity inversely correlates with the susceptibility to severe or fatal anaphylaxis. The use comprises assaying PAF-AH activity in a sample from the subject and comparing the measured activity to a reference value, wherein a lower level of measured PAF-AH activity relative to said reference level of PAF-AH activity indicates a presence of or susceptibility to severe or fatal anaphylaxis in the subject. A method for treating or preventing severe or fatal anaphylaxis in a subject is also provided. The method comprises increasing serum platelet activating factor acetylhydrolase (PAF-AH) concentration in the subject by administering to the subject, PAF-AH and/or a PAF receptor antagonist. A composition for treating severe or fatal anaphylaxis is also provided. | 2012-12-27 |
| 20120328597 | Topical Compositions Comprising Fermented Extracts of Traditional Chinese Medicinal (TCM) Ingredients, and Methods of Making and Using Same - The present invention relates to topical compositions containing fermented extracts of Traditional Chinese Medicinal (TCM) ingredients for improving the appearance and skin condition of the user. The topical compositions of the present invention are tailored for different users of different skin compositions according to TCM principles. The fermented TCM extracts are characterized by reduced odor and/or color in comparison with unfermented TCM extracts and are therefore more suitable for use in cosmetic products. | 2012-12-27 |
| 20120328598 | AGENTS AND MECHANISMS FOR TREATING HYPERCHOLESTEROLEMIA - A method of treating hypercholesterolemia in mammals, by administering an effective amount of a microbial fermentation product, and regulating genes involved in lipoprotein metabolism. A method of regulating cholesterol levels in a patient by administering an effective amount of a composition chosen from the group consisting of PAZ, specific components isolated from PAZ, chemically synthesized analogues of the components of PAZ, and regulating genes involved in lipoprotein metabolism. A method of treating high cholesterol levels in an individual by administering an effective amount of a microbial fermentation product, up-regulating the expression of at least one of the genes that encode ABCA1, ApoA1, and SRB1, and down-regulating the gene that encodes CETP. A method of preventing the onset of high cholesterol levels and/or a deleterious lipoprotein profile in an individual. | 2012-12-27 |
| 20120328599 | INHIBITORS OF RECEPTOR TYROSINE KINASES (RTK) AND METHODS OF USE THEREOF - The present invention provides moieties that bind to the asymmetric contact interface of a receptor tyrosine kinase (RTK), wherein the moieties inhibit ligand induced trans autophosphorylation of the RTK. The present invention also provides methods of treating or preventing an RTK-associated disease and methods for identifying moieties that bind to an asymmetric contact interface of an RTK. | 2012-12-27 |
| 20120328600 | INJECTION OF FIBRIN SEALANT USING RECONSTITUTED COMPONENTS IN SPINAL APPLICATIONS - A method of treating a disc that is leaking nucleus pulposus through at least one defect in the annulus fibrosus. The method includes injecting a fibrin sealant into the disc to reduce at least a portion of the at least one defect, wherein the fibrin sealant injected into the disc comprises fibrinogen and an activating compound, wherein at least a portion of the fibrin forms after injection, wherein the fibrinogen, the activating compound or both has been reconstituted with a solution containing at least one additive, with the proviso that a corticosteroid is absent from the fibrin sealant injected into the disc. | 2012-12-27 |
| 20120328601 | Modulation of Synaptic Maintenance - C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including treating and preventing neurodegenerative diseases such as Alzheimer's disease. | 2012-12-27 |
| 20120328602 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH CERAMIDE BIOSYNTHESIS - Provided are a pharmaceutical composition and a method for reducing, preventing, or delaying the development of a biological condition associated with administration of an opioid drug, in particular, tolerance to and/or physical dependence on an opioid drug. The pharmaceutical composition includes an opioid drug, a ceramide biosynthesis inhibitor and a pharmaceutically acceptable carrier. The method of treatment involves administration of an opioid drug and a ceramide biosynthesis inhibitor. Also provided are a method of screening for an agent that reduces, prevents or delays the development of tolerance to and/or physical dependence on an opioid drug as well as compositions comprising a dsRNA for inhibiting ceramide biosynthesis in a cell and a vector for expressing a shRNA for inhibiting ceramide biosynthesis in a cell. | 2012-12-27 |
| 20120328603 | ASSAYS AND METHODS USING BIOMARKERS - Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of one or more such biomarkers is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Certain biomarkers which may be examined include fucosyltransferases, in particular fucosyltransferase 3 (FUT3) and/or fucosyltransferase 6 (FUT6), as well as sialyl Lewis A and/or X antigens. Kits and articles of manufacture are also provided. | 2012-12-27 |
| 20120328604 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH AVB5 INTEGRIN - The present invention provides compositions and methods for treating and preventing disease associated with αvβ5 integrin by blocking binding to αvβ5 integrin. In particular, antibodies specific for αvβ5 integrin are useful for preventing, treating, and reversing sepsis. | 2012-12-27 |
| 20120328605 | COMPOSITIONS AND USES - The invention provides a TLR agonist and an antibody which binds to an antigen such as a β-amyloid antigen for use in stimulating an immune response to the antigen in an individual. The TLR agonist can be delivered at the same time as the antibody, less than 48 hours before the antibody or after the antibody. The compositions and methods provided are useful for prevention or treatment of Alzheimer's disease. | 2012-12-27 |
| 20120328606 | Methods Of Diagnosing And Treating Pulmonary Diseases Or Disorders - The present disclosure provides methods of diagnosing a subject as having a pulmonary disease or disorder, e.g., an eosinophilic disease or disorder based on the determination of white blood cell ratios. The disclosure also provides white blood cell ratio-based methods of treating, prognosing, or monitoring a pulmonary disease or disorder, as well as methods of methods of predicting a dosage regimen, identifying a candidate therapeutic agent, identifying a patient as a candidate for a therapeutic agent, and methods of designing a personalized therapy. | 2012-12-27 |
| 20120328607 | GENETIC MARKERS INDICATIVE OF A CANCER PATIENT RESPONSE TO TRASTUZUMAB (HERCEPTIN) - The invention relates to the fields of therapeutics and identifying candidates for therapy, in particular to a method of identifying candidates for trastuzumab (Herceptin®) therapy in a patient presenting with breast cancer based on the presence or absence of specific genetic markers in a tumor sample from said patient. | 2012-12-27 |
| 20120328608 | METHODS OF TREATING CANCER USING NOTCH ANTAGONISTS - The present invention relates to methods of treating cancer in general, and leukemia in particular, using Notch1 and Notch3 antagonists singly or in combination. Compositions and methods for the treatment and diagnosis of Notch-associated cancers are also provided. | 2012-12-27 |
| 20120328609 | Modulation of Axon Degeneration - The invention relates generally to treatment of neurological disorders and nervous system injuries. The invention specifically provides methods of using modulators of particular target proteins to modulate degeneration of neurons or portions thereof, such as axons. | 2012-12-27 |
| 20120328610 | TRIAZOLOPYRIDINES - The present invention relates to triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1 or TTK) inhibitors: Formula (I), in which R | 2012-12-27 |
| 20120328611 | SUBSTITUTED TRIAZOLOPYRIDINES - The present invention relates to triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1 or TTK) inhibitors: Formula (I), in which R | 2012-12-27 |
